Loss of expression of both miR-15/16 loci in CML transition to blast crisis.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
16 03 2021
Historique:
entrez: 10 4 2021
pubmed: 11 4 2021
medline: 10 9 2021
Statut: ppublish

Résumé

Despite advances that have improved the treatment of chronic myeloid leukemia (CML) patients in chronic phase, the mechanisms of the transition from chronic phase CML to blast crisis (BC) are not fully understood. Considering the key role of miR-15/16 loci in the pathogenesis of myeloid and lymphocytic leukemia, here we aimed to correlate the expression of miR-15a/16 and miR-15b/16 to progression of CML from chronic phase to BC. We analyzed the expression of the two miR-15/16 clusters in 17 CML patients in chronic phase and 22 patients in BC and in 11 paired chronic phase and BC CML patients. BC CMLs show a significant reduction of the expression of miR-15a/-15b/16 compared to CMLs in chronic phase. Moreover, BC CMLs showed an overexpression of miR-15/16 direct targets such as Bmi-1, ROR1, and Bcl-2 compared to CMLs in chronic phase. This study highlights the loss of both miR-15/16 clusters as a potential oncogenic driver in the transition from chronic phase to BC in CML patients.

Identifiants

pubmed: 33836616
pii: 2101566118
doi: 10.1073/pnas.2101566118
pmc: PMC7980455
pii:
doi:

Substances chimiques

BCL2 protein, human 0
BMI1 protein, human 0
MIRN15 microRNA, human 0
MIRN16 microRNA, human 0
MicroRNAs 0
Proto-Oncogene Proteins c-bcl-2 0
Polycomb Repressive Complex 1 EC 2.3.2.27
ROR1 protein, human EC 2.7.10.1
Receptor Tyrosine Kinase-like Orphan Receptors EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197706
Pays : United States

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

Blood. 2016 Jun 2;127(22):2742-50
pubmed: 27006386
N Engl J Med. 1999 Jul 15;341(3):164-72
pubmed: 10403855
J Biol Chem. 2005 Aug 26;280(34):30254-62
pubmed: 15927960
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):13069-13074
pubmed: 30478046
Science. 1984 Jun 8;224(4653):1117-21
pubmed: 6585957
N Engl J Med. 2005 Oct 27;353(17):1793-801
pubmed: 16251535
Leukemia. 2007 May;21(5):1116-22
pubmed: 17377594
Blood Cells Mol Dis. 2014 Dec;53(4):194-8
pubmed: 25084695
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
pubmed: 12434020
Nat Rev Genet. 2009 Oct;10(10):704-14
pubmed: 19763153
Proc Natl Acad Sci U S A. 1989 May;86(9):3379-83
pubmed: 2541445
Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11636-41
pubmed: 26324892
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
pubmed: 16166262
N Engl J Med. 2016 Jan 28;374(4):311-22
pubmed: 26639348
Blood. 2007 Jul 1;110(1):380-3
pubmed: 17360938
BMC Genomics. 2013 Mar 15;14:181
pubmed: 23496794
Lancet. 2014 Jun 28;383(9936):2239-52
pubmed: 24656536
Nat Med. 2013 Feb;19(2):202-8
pubmed: 23291630
Blood. 2009 Aug 20;114(8):1498-505
pubmed: 19556423
Clin Cancer Res. 2008 Jan 15;14(2):396-404
pubmed: 18223214
Int J Cancer. 2008 Sep 1;123(5):1190-5
pubmed: 18546292
Int J Hematol. 2005 Jul;82(1):42-7
pubmed: 16105758
Am J Med. 1987 Sep;83(3):445-54
pubmed: 3477958
Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12332-12340
pubmed: 32424097
Blood. 2008 May 1;111(9):4771-9
pubmed: 18227349
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Cancer Cell. 2010 Jan 19;17(1):28-40
pubmed: 20060366
Sci Transl Med. 2016 Sep 7;8(355):355ra117
pubmed: 27605552
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10731-10736
pubmed: 28923920
Hematology Am Soc Hematol Educ Program. 2007;:384-91
pubmed: 18024655
Cancer Res. 2009 Dec 1;69(23):9090-5
pubmed: 19903841
N Engl J Med. 1999 Apr 29;340(17):1330-40
pubmed: 10219069

Auteurs

Francesca Lovat (F)

Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210.
Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.

Pierluigi Gasparini (P)

Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210.
Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, 2308 NSW, Australia.

Giovanni Nigita (G)

Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210.
Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.

Karilyn Larkin (K)

Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.

John C Byrd (JC)

Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.

Mark D Minden (MD)

Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 2M9, Canada.

Michael Andreeff (M)

Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030.

Bing Z Carter (BZ)

Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030.

Carlo M Croce (CM)

Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210; carlo.croce@osumc.edu.
Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH